Bitter pill for AstraZeneca Pharma after reverse turnaround in Q4

AstraZeneca Pharma India lost 3.2% to Rs 960 at 13:21 IST on BSE after the company reported net loss of Rs 2.88 crore in Q4 March 2017, compared with net profit of Rs 0.56 crore in Q4 March 2016.

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 263.29 points, or 0.88%, to 30,196.54. The S&P BSE Small-Cap index was up 130.87 points, or 0.84% to 15,675.50

On the BSE, 7,662 shares were traded on the counter so far as against the average daily volumes of 6,031 shares in the past one quarter. The stock had hit a high of Rs 968 and a low of Rs 945 so far during the day. The stock had hit a 52-week high of Rs 1,151 on 9 May 2016 and a 52-week low of Rs 909 on 1 March 2017.

The stock had outperformed the market over the past one month till 9 May 2017, rising 2.76% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, gaining 5.09% as against Sensex's 5.81% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma India's total income dropped 26.66% to Rs 118.01 crore in Q4 March 2017 over Q4 March 2016.

AstraZeneca Pharma India is engaged in the development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. AstraZeneca Pharmaceuticals AB holds 75% stake in AstraZeneca Pharma India (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News